Induction of TNF alpha and IL-1 beta mRNA in monocytes by methylglyoxal- and advanced glycated endproduct-modified human serum albumin.
Webster
L
L
Immunology Dept, UMDS, St Thomas' Hospital, London, UK.
Abordo
E A
EA
Thornalley
P J
PJ
Limb
G A
GA
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D003208:Concanavalin A / Q000494:pharmacology; D017127:Glycation End Products, Advanced / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000096:biosynthesis*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D011765:Pyruvaldehyde / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D012709:Serum Albumin / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D003208:Concanavalin A; D017127:Glycation End Products, Advanced; D007375:Interleukin-1; D011765:Pyruvaldehyde; D012333:RNA, Messenger; D012709:Serum Albumin; D014409:Tumor Necrosis Factor-alpha; C067980:CD68 antigen, human; D000097382:CD68 Molecule